Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Background Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a
central role in the process of fibrosis. This study was designed to assess the safety …

Idiopathic pulmonary fibrosis is a major cause of death with few treatment options. Here, we
demonstrate the therapeutic efficacy for lung fibrosis of adult lung cell transplantation using …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal
disorder. Two US Food and Drug Administration–approved antifibrotic drugs, nintedanib and …

Idiopathic pulmonary fibrosis (IPF) is a debilitating condition where excess collagen
deposition occurs in the extracellular matrix. At first sight, it is expected that the level of …

Background The two 52-week INPULSIS trials investigated nintedanib versus placebo in
patients with IPF, FVC≥ 50% predicted and DLco 30–79% predicted. The 24-week …

Crohn's disease (CD) is a chronic relapsing and remitting disease that can affect any
segments of the gastrointestinal tract. More than 50% of patients with CD develop stricturing …

Real-world studies include a broader patient population for a longer duration than
randomised controlled trials (RCTs) and can provide relevant insights for clinical practice …

Fibrosis is the unrelenting deposition of excessively large amounts of insoluble interstitial
collagen due to profound matrigenic activities of wound-associated myofibroblasts during …